FENC FENNEC PHARMACEUTICALS INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1211583 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY71.1%
TTM net income YoY129.2%
TTM EPS YoY111.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin5.6%
Net margin3.1%
FCF margin—
EBITDA margin—
Returns
ROE9.1%
ROA3.1%
ROIC (approx.)—
Asset turnover1.00x
Leverage & solvency
Liabilities / assets41.1%
Debt / equity0.00x
Current ratio6.11x
Interest coverage11.66x
Cash quality & payout
Operating cash flow / net income1.55x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $44.64M | $47.54M |
| R&D expense | $250,000 | $307,000 |
| SG&A expense | $28.29M | $23.05M |
| Operating income | -$6.28M | $2.57M |
| Interest expense | $2.08M | $4.07M |
| Pretax income | -$9.63M | -$71,000 |
| Income tax | $106,000 | $365,000 |
| Net income | -$9.74M | -$436,000 |
| EPS (basic) | -0.34 | -0.02 |
| EPS (diluted) | -0.34 | -0.02 |
| Weighted avg. shares (diluted) | 28.58M | 27.29M |
| Balance sheet | ||
| Cash & equivalents | $36.79M | $26.63M |
| Current assets | $67.04M | $44.12M |
| Total assets | $70.55M | $44.95M |
| Current liabilities | $10.52M | $6.92M |
| Long-term debt | — | $19.34M |
| Total debt | — | $19.34M |
| Total liabilities | $35.08M | $50.82M |
| Shareholders' equity | $35.47M | -$5.87M |
| Net debt | — | -$7.30M |
| Shares outstanding | 34.16M | 27.53M |
| Cash flow statement | ||
| Operating cash flow | -$12.47M | $26.98M |
| Financing cash flow | $22.63M | -$13.62M |
| Stock-based compensation | $7.03M | $5.06M |
Free plan shows the latest 2 periods; Pro shows all 28 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.